Business Description
Genetic Analysis AS
ISIN : NO0010692130
Compare
Compare
Traded in other countries / regions
GEAN.Sweden8V8.Germany IPO Date
2021-10-28Description
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.06 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.41 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.14 | |||||
| Beneish M-Score | -2.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17 | |||||
| 3-Year EBITDA Growth Rate | 9.2 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | 0.1 | |||||
| 3-Year Book Growth Rate | -23.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.24 | |||||
| 9-Day RSI | 40.14 | |||||
| 14-Day RSI | 43.45 | |||||
| 6-1 Month Momentum % | -31.36 | |||||
| 12-1 Month Momentum % | -71.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.81 | |||||
| Quick Ratio | 1.71 | |||||
| Cash Ratio | 0.95 | |||||
| Days Inventory | 141.62 | |||||
| Days Sales Outstanding | 63.96 | |||||
| Days Payable | 291.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15 | |||||
| Shareholder Yield % | -12.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.68 | |||||
| Operating Margin % | -219.27 | |||||
| Net Margin % | -168.37 | |||||
| FCF Margin % | -127.49 | |||||
| ROE % | -69.2 | |||||
| ROA % | -44.46 | |||||
| ROIC % | -86.58 | |||||
| ROC (Joel Greenblatt) % | -330.9 | |||||
| ROCE % | -57.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.25 | |||||
| PB Ratio | 0.76 | |||||
| Price-to-Tangible-Book | 1.85 | |||||
| EV-to-EBIT | -0.75 | |||||
| EV-to-Forward-EBIT | -1.56 | |||||
| EV-to-EBITDA | -0.99 | |||||
| EV-to-Revenue | 1.26 | |||||
| EV-to-Forward-Revenue | 0.66 | |||||
| EV-to-FCF | -1.06 | |||||
| Price-to-Net-Current-Asset-Value | 3.7 | |||||
| Earnings Yield (Greenblatt) % | -132.43 | |||||
| FCF Yield % | -70.14 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers